biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA
MAIA Biotechnology
MAIA Biotechnology clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- honolulu, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 8
- Drugs
- 19
- Patents
- 10
MAIA Biotechnology projects
8 ClinicalTrials.gov programs sponsored by MAIA Biotechnology.
MAIA Biotechnology has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
12-Valent Pneumococcal Conjugate Vaccine
MAIA Biotechnology
Pneumococcal Vaccines
1 trial -
6-Thio-2'-Deoxyguanosine
MAIA Biotechnology
Carcinoma, Non-Small-Cell Lung
2 trials -
THIO-104
MAIA Biotechnology
Non-Small Cell Lung Cancer
1 trial -
THIO-101
MAIA Biotechnology
Non-Small Cell Lung Cancer
1 trial -
etrasimod
MAIA Biotechnology
Pouchitis
1 trial -
Fecal Microbiota Transplant (FMT)
MAIA Biotechnology
Chronic Pouchitis
1 trial -
ateganosine
MAIA Biotechnology
Resectable Hepatocellular Carcinoma
1 trial -
Blood ponction
MAIA Biotechnology
Alzheimer Blood Biomarkers
1 trial
Frequently asked questions
How many clinical projects does MAIA Biotechnology have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.